GNH USA

Europe — EMA

Muphoran (Fotemustine)

GNH USA supplies Muphoran (Fotemustine), a nitrosourea alkylating agent for malignant melanoma and high‑grade glioma. Request a quote for global supply.

Fotemustine

Request sourcing

1
Pack/s

What is Fotemustine?

Fotemustine, the active ingredient in Muphoran, is a nitrosourea alkylating agent presented as an injection for intravenous use. It is employed in the treatment of malignant melanoma and high‑grade glioma in adult patients.

GNH USA supplies Muphoran as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

What is Fotemustine used for?

Fotemustine is used in the management of malignant melanoma and certain brain tumors.

- Malignant melanoma: provides cytotoxic therapy aimed at reducing tumor burden. - High‑grade glioma: used as part of chemotherapy regimens to inhibit tumor growth. - Other brain tumors: employed to achieve disease control in selected intracranial neoplasms.

What are the side effects of Fotemustine?

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis following infusion. - Myelosuppression: reduced blood cell counts, especially neutrophils. - Fatigue: generalized tiredness during treatment.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe infection: due to profound neutropenia. - Hepatic toxicity: elevated liver enzymes or liver dysfunction.

What precautions apply to Fotemustine?

Precautions should be observed before and during treatment with Muphoran. - Renal function: assess creatinine clearance before infusion. - Hepatic function: monitor liver enzymes during therapy. - Hematologic status: check complete blood count prior to each dose. - Pregnancy: avoid use in pregnant women unless benefits outweigh risks. - Concomitant radiation: use caution as combined therapy may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Fotemustine interact with?

Potential drug interactions require careful management.

Major Interactions (Avoid): - Other alkylating agents: additive bone marrow suppression. - Anticoagulants: increased risk of bleeding due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - CYP450 inducers: may reduce plasma levels of fotemustine. - Anticonvulsants (e.g., carbamazepine): potential alteration of drug metabolism. - Immunosuppressants: heightened infection risk when combined.

Frequently asked questions

What is Muphoran used for?+
Muphoran, containing the active ingredient fotemustine, is indicated for the treatment of malignant melanoma and high‑grade glioma, as well as selected other brain tumors. It is used as part of a chemotherapy regimen to control tumor growth in adult patients.
How does fotemustine work?+
Fotemustine belongs to the nitrosourea class of alkylating agents. It forms covalent cross‑links in DNA strands, preventing replication and transcription. This DNA damage triggers cell death, particularly in rapidly dividing cancer cells, and its ability to cross the blood‑brain barrier makes it effective for intracranial tumors.
What is the usual dose of Muphoran?+
The dosing regimen for Muphoran is individualized by the prescribing oncologist. Dosage depends on factors such as patient weight, renal and hepatic function, and the specific treatment protocol. Clinicians determine the appropriate amount and schedule for each patient.
Is Muphoran safe in pregnancy or breastfeeding?+
Safety data for fotemustine during pregnancy and lactation are limited. Because of potential risks to the fetus and infant, Muphoran is generally avoided in pregnant or breastfeeding women unless the therapeutic benefit justifies the potential hazard. Consultation with a specialist is essential.
How do I order Muphoran from GNH USA?+
To order Muphoran, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.
How does Muphoran compare with the main alternative drug or class?+
The primary alternative to fotemustine is temozolomide, another alkylating agent used for brain tumors. Fotemustine has higher lipophilicity, allowing better penetration of the blood‑brain barrier, but it is associated with a distinct toxicity profile, including higher rates of pulmonary fibrosis. Choice of therapy depends on tumor type, patient tolerance, and clinical judgment.
What are the storage and handling requirements for Muphoran?+
Muphoran must be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Ensure that the cold‑chain is maintained during transport to preserve product stability.
How is Muphoran administered?+
Muphoran is supplied as a sterile injection for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, according to the dosing schedule prescribed by the oncologist. Infusion rates may be adjusted based on patient tolerance.
What are the most serious risks to watch for while on Muphoran?+
Serious adverse events include pulmonary fibrosis, severe infections due to profound neutropenia, and hepatic toxicity manifested by elevated liver enzymes or liver failure. Patients should be monitored regularly for respiratory symptoms, signs of infection, and liver function abnormalities throughout treatment.
Who should not use Muphoran?+
Muphoran is contraindicated in patients with severe bone‑marrow suppression, active uncontrolled infections, known hypersensitivity to fotemustine or other nitrosoureas, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with significant hepatic or renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Fotemustine
Route
Intravenous Use
Manufacturer
Les Laboratoires Servier (Suresnes)
Origin
EU

Related products

Muphoran

Muphoran

Fotemustine

Servier Austria Gmbh
EU
Muphoran

Muphoran

Fotemustine

Servier Benelux S.A./N.V.
EU
Muphoran

Muphoran

Fotemustine

Servier Hellas Pharmaceuticals Ltd
EU
Muphoran

Muphoran

Fotemustine

Les Laboratoires Servier (Suresnes)
EU